ORLANDO , Fla. - MedImmune showed off its fresh solution to the knotty problem of neutralizing insulin-like growth factor, a key player in the growth and proliferation of many solid tumors, at the American Association for Cancer Research annual meeting April 4, with a poster on the activity of its MIDI-573. The novel approach taken by MedImmune, AstraZeneca's biologics business, is to block the IGF pathway by blocking the ligand that binds the receptor, overcoming the limitations others have run...